Harbin Medisan Pharmaceutical Co Ltd (002900) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Harbin Medisan Pharmaceutical Co Ltd (002900) has a cash flow conversion efficiency ratio of -0.008x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-15.53 Million ≈ $-2.27 Million USD) by net assets (CN¥1.90 Billion ≈ $278.76 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 002900 days of operational coverage to measure how many days the company can operate on defensive assets alone.
Harbin Medisan Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Harbin Medisan Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Harbin Medisan Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Harbin Medisan Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jinfa Labi Maternity & Baby Articles Co Ltd
SHE:002762
|
-0.014x |
|
Hunan Lead Power Dazhi Technology Inc Co
SHE:300530
|
-0.195x |
|
PKU HealthCare Corp Ltd
SHE:000788
|
0.076x |
|
Schoeller-Bleckmann Oilfield Equipment Aktiengesellschaft
VI:SBO
|
0.045x |
|
TWC Enterprises Ltd
TO:TWC
|
0.081x |
|
I-Mab
NASDAQ:IMAB
|
0.007x |
|
Net Holding AS
IS:NTHOL
|
0.017x |
|
Utechzone Co Ltd
TWO:3455
|
0.041x |
Annual Cash Flow Conversion Efficiency for Harbin Medisan Pharmaceutical Co Ltd (2012–2024)
The table below shows the annual cash flow conversion efficiency of Harbin Medisan Pharmaceutical Co Ltd from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Harbin Medisan Pharmaceutical Co Ltd.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥2.16 Billion ≈ $316.68 Million |
CN¥30.69 Million ≈ $4.49 Million |
0.014x | -14.66% |
| 2023-12-31 | CN¥2.15 Billion ≈ $314.35 Million |
CN¥35.69 Million ≈ $5.22 Million |
0.017x | -76.43% |
| 2022-12-31 | CN¥2.05 Billion ≈ $300.27 Million |
CN¥144.64 Million ≈ $21.17 Million |
0.070x | +1290.28% |
| 2021-12-31 | CN¥2.12 Billion ≈ $309.71 Million |
CN¥-12.53 Million ≈ $-1.83 Million |
-0.006x | -135.40% |
| 2020-12-31 | CN¥1.79 Billion ≈ $262.16 Million |
CN¥-4.51 Million ≈ $-659.52K |
-0.003x | -101.46% |
| 2019-12-31 | CN¥1.85 Billion ≈ $270.96 Million |
CN¥320.14 Million ≈ $46.85 Million |
0.173x | +16.45% |
| 2018-12-31 | CN¥1.97 Billion ≈ $288.24 Million |
CN¥292.46 Million ≈ $42.80 Million |
0.148x | +21.92% |
| 2017-12-31 | CN¥1.83 Billion ≈ $268.51 Million |
CN¥223.46 Million ≈ $32.70 Million |
0.122x | -57.43% |
| 2016-12-31 | CN¥808.17 Million ≈ $118.26 Million |
CN¥231.18 Million ≈ $33.83 Million |
0.286x | +3.68% |
| 2015-12-31 | CN¥727.97 Million ≈ $106.53 Million |
CN¥200.85 Million ≈ $29.39 Million |
0.276x | +44.50% |
| 2014-12-31 | CN¥609.16 Million ≈ $89.14 Million |
CN¥116.31 Million ≈ $17.02 Million |
0.191x | -58.28% |
| 2013-12-31 | CN¥365.13 Million ≈ $53.43 Million |
CN¥167.10 Million ≈ $24.45 Million |
0.458x | +27.29% |
| 2012-12-31 | CN¥342.72 Million ≈ $50.15 Million |
CN¥123.22 Million ≈ $18.03 Million |
0.360x | -- |
About Harbin Medisan Pharmaceutical Co Ltd
Harbin Medisan Pharmaceutical Co., Ltd. engages in the research, development, production, and sale chemical pharmaceutical preparations in China. The company offers various drugs for nervous system, cardiovascular system, systemic anti-infective, muscle and skeletal system, nutritional infusion, and body fluid balance infusion; and other products, including oxaliplatin for injection, calcium foli… Read more